RxDoctor Payments Data

Judy Doong, MD

MOHS-Micrographic Surgery · Reno, NVNPI 1215326236

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,512 and has fallen 88.0% since, to $302 in 2025.

$6,883in general payments, 2019–2025

Across 196 payments — averaging $35.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dermavant Sciences, Inc.$929
  • AbbVie$858
  • E.r. Squibb & Sons, L.L.C.$790
  • Johnson & Johnson$638
  • Sun Pharmaceutical Industries Inc.$483
  • Pfizer$420
  • plus $3K from 15 others

What the payments were for

  • Food & beverage$6,58996%
  • Education$2944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$118,521
Medicare patients
265
Services billed
2,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate29$2,089
Fluorouracil17$1,509
Ketoconazole52$790
Gentamicin Sulfate19$320
Clotrimazole12$213
Econazole Nitrate12$181
Triamcinolone Acetonide34$159
Nystatin20$139
ValacyclovirValacyclovir Hcl15$54

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →